Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:IPA
DateTimeSourceHeadlineSymbolCompany
05/09/20228:18AMInvestorsHub NewsWireIPA's Subsidiary BioStrand Secures Second VLAIO Research GrantTSXV:IPAImmunoPrecise Antibodies Ltd
04/14/20227:06AMInvestorsHub NewsWireIPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and OfferingsTSXV:IPAImmunoPrecise Antibodies Ltd
03/29/202210:48AMInvestorsHub NewsWireIPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial IntelligenceTSXV:IPAImmunoPrecise Antibodies Ltd
03/14/20228:04AMInvestorsHub NewsWireIPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of DefenseTSXV:IPAImmunoPrecise Antibodies Ltd
03/09/20227:07AMInvestorsHub NewsWireIPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03TSXV:IPAImmunoPrecise Antibodies Ltd
04/08/20217:08AMInvestorsHub NewsWireImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's DiseaseTSXV:IPAImmunoPrecise Antibodies Ltd
02/13/202112:25AMPR Newswire (Canada)TSX Venture Exchange Stock Maintenance BulletinsTSXV:IPAImmunoPrecise Antibodies Ltd
12/23/20206:30AMPR Newswire (Canada)ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock ExchangeTSXV:IPAImmunoPrecise Antibodies Ltd
12/21/20207:12AMPR Newswire (Canada)ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal YearTSXV:IPAImmunoPrecise Antibodies Ltd
12/14/20206:20AMPR Newswire (Canada)ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine CandidateTSXV:IPAImmunoPrecise Antibodies Ltd
12/11/20206:45AMPR Newswire (Canada)ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2TSXV:IPAImmunoPrecise Antibodies Ltd
11/25/202012:46PMPR Newswire (Canada)ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™TSXV:IPAImmunoPrecise Antibodies Ltd
11/23/20206:00AMPR Newswire (Canada)IPA Selects Polytope™ Formulations for Pre-Clinical StudiesTSXV:IPAImmunoPrecise Antibodies Ltd
11/19/20206:00AMPR Newswire (Canada)ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious DiseaseTSXV:IPAImmunoPrecise Antibodies Ltd
11/17/20207:01PMPR Newswire (Canada)ImmunoPrecise Antibodies Confirms Effective Date of Share ConsolidationTSXV:IPAImmunoPrecise Antibodies Ltd
11/09/20208:11AMPR Newswire (Canada)ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration StatementTSXV:IPAImmunoPrecise Antibodies Ltd
11/04/20206:08PMPR Newswire (Canada)ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq ListingTSXV:IPAImmunoPrecise Antibodies Ltd
11/03/20206:30AMPR Newswire (Canada)ImmunoPrecise Antibodies and Mila Announce Strategic AI PartnershipTSXV:IPAImmunoPrecise Antibodies Ltd
10/27/20206:28AMPR Newswire (Canada)ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic ProductsTSXV:IPAImmunoPrecise Antibodies Ltd
10/08/20206:30AMPR Newswire (Canada)IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic TestTSXV:IPAImmunoPrecise Antibodies Ltd
10/06/20206:30AMPR Newswire (Canada)IPA's CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN TelevisionTSXV:IPAImmunoPrecise Antibodies Ltd
10/05/20206:30AMPR Newswire (Canada)ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & FriendsTSXV:IPAImmunoPrecise Antibodies Ltd
09/29/20208:10AMPR Newswire (Canada)ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021TSXV:IPAImmunoPrecise Antibodies Ltd
09/28/202010:59AMPR Newswire (Canada)IPA CEO Dr. Jennifer Bath to Appear Live Today on Bloomberg TelevisionTSXV:IPAImmunoPrecise Antibodies Ltd
09/28/20206:30AMPR Newswire (Canada)ImmunoPrecise to Present at the Virtual Gravitas Healthcare Investor DayTSXV:IPAImmunoPrecise Antibodies Ltd
09/25/20206:30AMPR Newswire (Canada)ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical TrialsTSXV:IPAImmunoPrecise Antibodies Ltd
09/22/20206:30AMPR Newswire (Canada)IPA Europe Significantly Expands its Capabilities, Releasing its Second-Generation B Cell Select ™TSXV:IPAImmunoPrecise Antibodies Ltd
09/17/20206:30AMPR Newswire (Canada)ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with ZymeworksTSXV:IPAImmunoPrecise Antibodies Ltd
09/10/20206:30AMPR Newswire (Canada)ImmunoPrecise Commences Application Process to Dual List on NASDAQTSXV:IPAImmunoPrecise Antibodies Ltd
09/09/20204:37PMPR Newswire (Canada)ImmunoPrecise Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 202...TSXV:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:TSXV:IPA